Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

Trial Profile

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Letrozole; Trastuzumab; Trastuzumab
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms AWARE-1
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 12 Nov 2019 According to Oncolytics media release, final data from this study is expected in Q2 2020
    • 12 Nov 2019 According to Oncolytics media release, enrolment is expected to be completed by Q1 2020
    • 12 Nov 2019 According to Oncolytics media release, Interim data from AWARE-1 breast cancer study is expected in Q4 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top